(Q37989260)

English

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

scientific article published on 28 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study (English)

1 reference

Europe PubMed Central

26 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

François-Clément Bidard

13

object named as

François-Clément Bidard

0 references

Emmanuelle Charafe-Jauffret

10

object named as

Emmanuelle Charafe-Jauffret

0 references

object named as

Patrice Viens

14

0 references

Joseph Gligorov

object named as

Joseph Gligorov

6

0 references

Thomas Bachelot

9

object named as

Thomas Bachelot

1 reference

Europe PubMed Central

26 August 2017

author name string

Jean-Yves Pierga

1

1 reference

Europe PubMed Central

26 August 2017

Thierry Petit

2

1 reference

Europe PubMed Central

26 August 2017

Thierry Delozier

3

1 reference

Europe PubMed Central

26 August 2017

Jean-Marc Ferrero

4

1 reference

Europe PubMed Central

26 August 2017

Mario Campone

5

1 reference

Europe PubMed Central

26 August 2017

Florence Lerebours

7

1 reference

Europe PubMed Central

26 August 2017

Henri Roché

8

1 reference

Europe PubMed Central

26 August 2017

Maria Pavlyuk

11

1 reference

Europe PubMed Central

26 August 2017

Sandrine Kraemer

12

1 reference

Europe PubMed Central

26 August 2017

publication date

28 February 2012

1 reference

Europe PubMed Central

26 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 August 2017

13

1 reference

Europe PubMed Central

26 August 2017

4

1 reference

Europe PubMed Central

26 August 2017

375-384

1 reference

Europe PubMed Central

26 August 2017

Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of inflammatory breast cancer (IBC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970049-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70049-9

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37989260&oldid=1898845669"